Company news

Fortress Biotech, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

August 13, 2026

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financing

July 28, 2026

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing

July 27, 2026

Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference

May 18, 2026

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 14, 2026

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

May 4, 2026

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

April 21, 2026

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

March 30, 2026

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

March 29, 2026

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

March 17, 2026

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

February 22, 2026

Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

February 22, 2026

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

February 22, 2026

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO, the First and Only Approved Treatment for Menkes Disease in the United States

January 14, 2026

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

January 13, 2026

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

December 15, 2025

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 14, 2025

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 13, 2025

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

November 6, 2025

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

November 4, 2025

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout

October 21, 2025

Journey Medical Corporation to Participate in October 2025 Investor Conferences

October 7, 2025

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing

October 1, 2025

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

October 1, 2025

Journey Medical Corporation to Participate in September 2025 Investor Conferences

September 2, 2025

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 2, 2025

Journey Medical Corporation to Present at the Emerging Growth Conference

August 17, 2025

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

August 14, 2025

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

August 6, 2025

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

August 4, 2025

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

July 13, 2025

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

July 6, 2025

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

June 23, 2025

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

May 30, 2025

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 15, 2025

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

May 12, 2025

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 7, 2025

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

March 31, 2025

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

March 31, 2025

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

March 23, 2025

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

March 18, 2025

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

March 17, 2025

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

March 11, 2025

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

March 4, 2025

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

February 26, 2025

Mustang Bio Announces Closing of $8 Million Public Offering

February 9, 2025

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

January 26, 2025

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

January 5, 2025

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

December 12, 2024

Older news releases →

Calls

Decks

The 5 newest of 24 decks. Every deck is listed under its year.